New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.

Matthew J. Akiyama, Joy I. Piotrowski, Marina M. Roytman, Siu M A Chan, Leena K. Hong, Leslie Huddleston, Ruby Trujillo, Naoky C S Tsai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recent advances in treatment of chronic hepatitis C virus have improved significantly due to the introduction of two new protease inhibitors-telaprevir and boceprevir. In combination with the previous standard of care, peginterferon and ribavirin, telaprevir and boceprevir have demonstrated improved sustained virologic response rates for HCV genotype 1 patients by approximately 30%. The purpose of this study was to assess the validity of large clinical trial data with respect to efficacy and side effects in a community setting in Honolulu, Hawai'i. This retrospective study was performed by reviewing the charts of 59 chronic HCV patients who were started on triple therapy from July 1, 2011 to July 7, 2012. Sustained virologic response was attained by 73% of patients treated with telaprevir and 46% of patients treated with boceprevir respectively. Our clinical experience with telaprevir demonstrates that SVR rates are compatible with published literature values. Rates of SVR in our cohort were also similar to those reported in cirrhotic patients - about 50%. Due to small number of patients treated with a boceprevir-based regimen, it is difficult to compare our experience with pivotal trial experience. The side effect profiles for the two protease inhibitors were similar to the literature values except for more rectal irritation and a higher incidence and severity of anemia on telaprevir therapy in the clinical setting. While not intended to be conclusive, our study demonstrates that clinical trial data are largely compatible with the outcomes obtained in our community setting.

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalHawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health
Volume72
Issue number9 Suppl 4
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Life Change Events
Chronic Hepatitis C
Protease Inhibitors
Therapeutics
Clinical Trials
Ribavirin
Standard of Care
Hepacivirus
Anemia
Retrospective Studies
Genotype
telaprevir
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New triple therapy for chronic hepatitis C : real life clinical experience in a community setting. / Akiyama, Matthew J.; Piotrowski, Joy I.; Roytman, Marina M.; Chan, Siu M A; Hong, Leena K.; Huddleston, Leslie; Trujillo, Ruby; Tsai, Naoky C S.

In: Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, Vol. 72, No. 9 Suppl 4, 09.2013, p. 6-13.

Research output: Contribution to journalArticle

Akiyama, MJ, Piotrowski, JI, Roytman, MM, Chan, SMA, Hong, LK, Huddleston, L, Trujillo, R & Tsai, NCS 2013, 'New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.', Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, vol. 72, no. 9 Suppl 4, pp. 6-13.
Akiyama, Matthew J. ; Piotrowski, Joy I. ; Roytman, Marina M. ; Chan, Siu M A ; Hong, Leena K. ; Huddleston, Leslie ; Trujillo, Ruby ; Tsai, Naoky C S. / New triple therapy for chronic hepatitis C : real life clinical experience in a community setting. In: Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health. 2013 ; Vol. 72, No. 9 Suppl 4. pp. 6-13.
@article{68d013ea97dc452095517403f944ee9e,
title = "New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.",
abstract = "Recent advances in treatment of chronic hepatitis C virus have improved significantly due to the introduction of two new protease inhibitors-telaprevir and boceprevir. In combination with the previous standard of care, peginterferon and ribavirin, telaprevir and boceprevir have demonstrated improved sustained virologic response rates for HCV genotype 1 patients by approximately 30{\%}. The purpose of this study was to assess the validity of large clinical trial data with respect to efficacy and side effects in a community setting in Honolulu, Hawai'i. This retrospective study was performed by reviewing the charts of 59 chronic HCV patients who were started on triple therapy from July 1, 2011 to July 7, 2012. Sustained virologic response was attained by 73{\%} of patients treated with telaprevir and 46{\%} of patients treated with boceprevir respectively. Our clinical experience with telaprevir demonstrates that SVR rates are compatible with published literature values. Rates of SVR in our cohort were also similar to those reported in cirrhotic patients - about 50{\%}. Due to small number of patients treated with a boceprevir-based regimen, it is difficult to compare our experience with pivotal trial experience. The side effect profiles for the two protease inhibitors were similar to the literature values except for more rectal irritation and a higher incidence and severity of anemia on telaprevir therapy in the clinical setting. While not intended to be conclusive, our study demonstrates that clinical trial data are largely compatible with the outcomes obtained in our community setting.",
author = "Akiyama, {Matthew J.} and Piotrowski, {Joy I.} and Roytman, {Marina M.} and Chan, {Siu M A} and Hong, {Leena K.} and Leslie Huddleston and Ruby Trujillo and Tsai, {Naoky C S}",
year = "2013",
month = "9",
language = "English (US)",
volume = "72",
pages = "6--13",
journal = "Hawaii Medical Journal",
issn = "2165-8218",
publisher = "University Clinical, Education & Research Associates (UCERA)",
number = "9 Suppl 4",

}

TY - JOUR

T1 - New triple therapy for chronic hepatitis C

T2 - real life clinical experience in a community setting.

AU - Akiyama, Matthew J.

AU - Piotrowski, Joy I.

AU - Roytman, Marina M.

AU - Chan, Siu M A

AU - Hong, Leena K.

AU - Huddleston, Leslie

AU - Trujillo, Ruby

AU - Tsai, Naoky C S

PY - 2013/9

Y1 - 2013/9

N2 - Recent advances in treatment of chronic hepatitis C virus have improved significantly due to the introduction of two new protease inhibitors-telaprevir and boceprevir. In combination with the previous standard of care, peginterferon and ribavirin, telaprevir and boceprevir have demonstrated improved sustained virologic response rates for HCV genotype 1 patients by approximately 30%. The purpose of this study was to assess the validity of large clinical trial data with respect to efficacy and side effects in a community setting in Honolulu, Hawai'i. This retrospective study was performed by reviewing the charts of 59 chronic HCV patients who were started on triple therapy from July 1, 2011 to July 7, 2012. Sustained virologic response was attained by 73% of patients treated with telaprevir and 46% of patients treated with boceprevir respectively. Our clinical experience with telaprevir demonstrates that SVR rates are compatible with published literature values. Rates of SVR in our cohort were also similar to those reported in cirrhotic patients - about 50%. Due to small number of patients treated with a boceprevir-based regimen, it is difficult to compare our experience with pivotal trial experience. The side effect profiles for the two protease inhibitors were similar to the literature values except for more rectal irritation and a higher incidence and severity of anemia on telaprevir therapy in the clinical setting. While not intended to be conclusive, our study demonstrates that clinical trial data are largely compatible with the outcomes obtained in our community setting.

AB - Recent advances in treatment of chronic hepatitis C virus have improved significantly due to the introduction of two new protease inhibitors-telaprevir and boceprevir. In combination with the previous standard of care, peginterferon and ribavirin, telaprevir and boceprevir have demonstrated improved sustained virologic response rates for HCV genotype 1 patients by approximately 30%. The purpose of this study was to assess the validity of large clinical trial data with respect to efficacy and side effects in a community setting in Honolulu, Hawai'i. This retrospective study was performed by reviewing the charts of 59 chronic HCV patients who were started on triple therapy from July 1, 2011 to July 7, 2012. Sustained virologic response was attained by 73% of patients treated with telaprevir and 46% of patients treated with boceprevir respectively. Our clinical experience with telaprevir demonstrates that SVR rates are compatible with published literature values. Rates of SVR in our cohort were also similar to those reported in cirrhotic patients - about 50%. Due to small number of patients treated with a boceprevir-based regimen, it is difficult to compare our experience with pivotal trial experience. The side effect profiles for the two protease inhibitors were similar to the literature values except for more rectal irritation and a higher incidence and severity of anemia on telaprevir therapy in the clinical setting. While not intended to be conclusive, our study demonstrates that clinical trial data are largely compatible with the outcomes obtained in our community setting.

UR - http://www.scopus.com/inward/record.url?scp=84894134567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894134567&partnerID=8YFLogxK

M3 - Article

C2 - 24052911

AN - SCOPUS:84894134567

VL - 72

SP - 6

EP - 13

JO - Hawaii Medical Journal

JF - Hawaii Medical Journal

SN - 2165-8218

IS - 9 Suppl 4

ER -